Background: The prognosis of gallbladder carcinoma is poor; therefore, investigating the efficacy of new chemotherapy agents is essential for the treatments for this tumor. Recently, several studies have reported clinical trials using gemcitabine as treatment for advanced gallbladder cancers. However, the antitumor effects of gemcitabine on gallbladder carcinoma have not been examined in in vitro and in vivo model systems.
Using a newly-devised model of nude mice inoculated orthotopically with gallbladder cancer, we found that gemcitabine treatment of gallbladder cancer may inhibit tumor progression and prolongs survival by inhibiting cell proliferation and inducing apoptosis.
Gallbladder cancer is the most common malignancy in the biliary tract. 1 Since symptoms from gallbladder cancer manifest themselves late in the disease course, tumors often are detected only at an advanced stage, when patients may not qualify for surgical treatment. For this reason, successful chemotherapy is especially important for cases of advanced gallbladder cancer. Recently, several reports have described gemcitabine treatment as an effective new regimen for treating gallbladder cancers. [2] [3] [4] [5] [6] [7] Gemcitabine is a novel nucleoside analogue that requires phosphorylation to become an active metabolite, gemcitabine triphosphate. Since gemcitabine triphosphate is a competitor of deoxycytidine triphosphate for incorporation into DNA, its presence inhibits DNA synthesis. Gemcitabine activity has been shown to function broadly in a variety of tumors and is currently used to treat nonsmall-cell lung cancer and pancreatic cancer in Japan. 8, 9 Phase II studies in Western countries, as well as in Japan, of single-agent gemcitabine treatment of patients with biliary tract cancer proved efficacious to some degree, with manageable toxicity. [2] [3] [4] [5] [6] [7] 10 The murine orthotopic model is useful for determining the effectiveness of a chemotherapeutic agent and the most efficient mechanism of administration. 11, 12 Previously, no animal model for examining the effects of chemotherapeutics on biliary tract cancers existed. However, our group has recently established an orthotopic gallbladder-cancer model useful for drug tests. 13, 14 In this paper, we examined the effect of gemcitabine in vivo using this gallbladder cancer model. Our results showed that decreased cell proliferation and increased apoptosis correlated with prolonged survival.
MATERIALS AND METHODS

Cell Lines and Cell Culture Conditions
Four biliary tract carcinoma cell lines, 1 bile duct carcinoma cell line (SK-ChA-1), and 3 gallbladder carcinomas cell lines (NOZ, TGBC-1, MZ-1), were used in this study. [15] [16] [17] Cells were cultured at 37°C in DMEM (Nissui, Tokyo, Japan) supplemented with 10% fetal calf serum (FCS, Sigma, St.Louis, Mo) under a humidified atmosphere containing 5% CO 2 .
Comparative Cytotoxicity Assays for Gemcitabine and 5-FU
The cytotoxicity for gemcitabine was assessed in the 4 biliary tract cancer cell lines using a WST-1 Cell Counting Kit (Wako, Osaka, Japan). These cell lines were cultured at a density of 1500-3000 cells/well in 96-well micro-plates with 100 ll conditioned medium and grown overnight at 37°C in an atmosphere containing 5% CO 2 . Twenty-four hours later, gemcitabine was dissolved in medium at nine different concentrations (100 lM-0.256 nM) and added to the plates at a volume of 100 ll per well. The plates were incubated for 72 h with the chemotherapeutic agent. Then, 10 ll of the Cell Counting Kit (WST-1, HE-PES, and 1-Methoxy PMS) was added to each well and incubated for another 2 or 3h at 37°C. The absorbance was read at 450 nm on a plate-spectrophotometer (BIO-RAD model 450). Absorbance values were expressed as a percentage of untreated controls and an inhibition concentration 50 (IC 50 ) was calculated. The IC 50 values represent the means of at least four independent experiments.
Animals and Orthotopic Implantation of Tumor Cells
Two-week-old athymic BALB/c male nude mice obtained from CLEA Japan Inc. (Tokyo, Japan) were used in this study. For orthotopic inoculation, we used an NOZ cell line among the 4 cell lines in the present in vivo study because NOZ cells yield a steady high frequency of tumor formation at the gallbladder and have a high potential of tumor growth and metastasis. NOZ cells were isolated from ascites derived from a 48-year-old female patient with gallbladder cancer. 15 The method used for inducing orthotopic gallbladder cancers in the mice has been described previously. 13, 14 Briefly, NOZ cells were suspended in 50 ll of serum-free medium. Nude mice were anesthetized and laparotomy was done. After the cystic duct was ligated on its proximal side with 7-0 Prolene (Ethicon, Inc., Somerville, NJ), the fundus of gallbladder was ligated to support. After removing the bile juice, NOZ cells were injected with a 27-gauge Myjectoer syringe (Termo Corporation, Tokyo, Japan) into the lumen of the gallbladder. Immediately after injection, ligation was performed distally to the injection site.
Mice were kept at the Animal Care and Use Facilities at Kobe University Graduate School of Medical Sciences under specific pathogen-free conditions. All experiments were approved by the Animal Care and Ethics Committee of the Kobe University Graduate School of Medical Sciences.
Experimental Conditions for Gemcitabine Therapy for Established Gallbladder Carcinoma
Gemcitabine was supplied by Eli Lilly Japan (Kobe, Japan). Seven days after implantation of NOZ cells into the gallbladder, five mice were killed, and the presence of cancer lesions was determined and confirmed histologically. Mice were randomized into four groups as follows: (a) Group A (n = 10), beginning on the seventh day after implantation of NOZ cells, twice weekly intra-peritoneal injections of 0.9% sodium chloride were continued for three weeks, and animals were then sacrificed on the 28th day after implantation, (b) Group B (n = 10), beginning on the seventh day after implantation of NOZ cells, twice weekly intra-peritoneal injections of 125 mg / kg gemcitabine were continued for three weeks, and animals were then sacrificed on the 28th day after implantation, (c) Group C (n = 10), beginning on the seventh day after implantation of NOZ cells, twice weekly intra-peritoneal injection of 125 mg / kg gemcitabine were continued for three weeks, and the survival duration was measured, and (d) Group D (n = 6), no treatment was administered after implantation of NOZ cells and survival duration was measured.
Histological Studies
When the mice were sacrificed, tumor status, the presence or absence of liver, lung and lymph node metastases, and the presence or absence of peritoneal dissemination were recorded. Histopathology using H & E staining confirmed the identity of the disease.
Immunohistochemical Determination of PCNA and TUNEL (Apoptotic Cells)
For immunohistochemistry procedures, the tumors were fixed in phosphate-buffered formalin, embedded in paraffin, cut in 4-lm thickness, and stained. Immunohistochemical analysis of proliferating cell nuclear antigen (PCNA) was performed using a labeled streptavidin-biotin technique described previously. 18 Anti-PCNA monoclonal antibody PC 10 (DAKO, Carpenteria, CA), which reacts exclusively with nuclei, was used at a dilution of 1:200. The number of PCNA-positive cells was counted in five high-power fields (0.135 mm 2 fields at x 200 magnification) selected at random, and the PCNA labeling index for each field was calculated as the percent of PCNA-positive cells (relative to the total). Apoptosis in tumor cells was detected using the terminal deoxynucleotidyl-transferase-mediated d-UTP-biotin nick end-labeling (TUNEL) assay, as described previously. 19 In the same manner as PCNA, five fields (0.135 mm 2 fields at x 200 magnification) were selected at random, and the apoptotic index of each field was calculated as the percent of TUNEL-positive cells.
Statistical Analysis
Statistical analyses were performed using StatView (Abacus Concepts Inc, Berkeley, Calif). Survival curves were computed using the Kaplan-Meier method and compared using the log-rank test. PCNA-labeling indices and apoptotic indices were assessed using unpaired StudentÕs t-test. The incidence of metastasis was compared using FisherÕs exact test. P < 0.05 was considered statistically significant.
RESULTS
Gemcitabine Sensitivity in Biliary Tract Cancer Cell Lines
Gemcitabine IC 50 of the biliary tract cancer cell lines, SK-ChA-1, NOZ, MZ-1 and TGBC-1, were 0.0052 lM, 0.021 lM, 0.16 lM, and 0.037 lM, respectively. SK-ChA-1 showed the highest sensitivity (5.2 nM). The gemcitabine sensitivity of the four biliary tract cancer cell lines was similar in a dose dependent manner (Fig. 1) .
Effectiveness of Gemcitabine in Suppressing the Invasion and Metastasis of NOZ Gallbladder Cancer Cells Inoculated Orthotopically into Nude Mice
Because of the high frequency of orthotopic tumorigenecity and metastatic potential, we used NOZ for in vivo experiment. Table 1 shows the incidence of gallbladder tumors and metastases with and without gemcitabine administration in mice on the 28th day after orthotopic inoculation of NOZ cells. At the time of sacrifice, macroscopically visible gallbladder tumors were present with direct liver invasion in all Group A mice. Almost all mice in Group A had metastases in multiple organs. In contrast, no tumors were visible in Group B mice (P < 0.01), and although a residue of cancer cells was observed histologically in 70% of Group B mice, no metastases were detected (Fig. 2) .
Effectiveness of Gemcitabine for Survival Duration
In Groups C and D, no apparent side effects (including loss of body weight or abnormal behavior) were observed throughout the treatment. At the time of death, all mice in Group D had huge gallbladder tumors, liver invasion, lung metastasis, lymph node metastasis, and peritoneal dissemination. The survival duration of mice treated with gemcitabine (Group C) ranged between 47 and 71 days (mean 59.6 days), significantly longer than the survival duration of Group D mice (range 32-38 days, mean 33.6 days) (Fig. 3) .
PCNA Expression and Labeling Index, and TUNEL Assay and Apoptotic Index
Examples of staining results for PCNA immunohistochemistry and TUNEL assays in mice of Group A and B are shown in Fig. 4 . The PCNA labeling indices of tumors from mice treated with gemcitabine (Group B) were significantly lower than those from mice treated with sodium chloride (Group A) (P < 0.01) (Fig. 5A) . The apoptotic indices of tumors from mice treated with gemcitabine (Group B) were significantly higher than those from mice treated with sodium chloride (Group A) (P < 0.01) (Fig. 5B) .
DISCUSSION
Our studies confirm that the administration of gemcitabine inhibits the growth and metastasis of human gallbladder cancers established in the gallbladders of athymic nude mice. Using this model, we have shown that inhibiting cell proliferation and inducing apoptosis can inhibit tumor progression and prolong survival in gallbladder cancers.
Although 5-FU has been widely used in chemotherapy for gallbladder cancer, there is little evidence of its effectiveness. In previous studies, we have shown that gallbladder carcinomas acquire resistance to 5-FU in vivo, as well as in vitro, via increased expression of thymidylate synthase or dihydropyrimidine dehydrogenase. 16, 20 Similar mechanisms are likely to contribute to the problematic nature of 5-FU-based chemotherapy for advanced gallbladder cancers.
As an alternative to 5-FU, several clinical studies have demonstrated that gemcitabine is efficacious as a single agent, or in combination with other drugs, against biliary tract cancers, including gallbladder cancer. [2] [3] [4] [5] [6] [7] 10 Despite these promising results, no experimental study of gemcitabineÕs efficacy for biliary tract carcinomas has been reported. Therefore, we conducted in vitro and in vivo gemcitabine experiments examining its effects on NOZ human gallbladder cancer cells implanted into the gallbladders of nude mice.
First, comparative cytotoxicity assays revealed that the inhibitory effect of gemcitabine is a generalized effect for biliary tract cancer cells. Next, we performed an in vivo assay using an orthotopic inoculation model using NOZ cells. Gemcitabine treatment clearly inhibited tumor growth and metastasis in this model.
Several aspects of the orthotopic inoculation model make it useful for testing the effects of gemcitabine on gallbladder cancer. Relative to ectopic (i.e. subcutaneous) inoculation, orthotopic inoculation is likely to provide information not only on the tumorigenicity, invasiveness, and metastatic potential of tumor cells, but also on their responsiveness to drugs. Furthermore, tumors generated by orthotopic inoculation display characteristics that are similar and unique to human gallbladder cancers. This animal model demonstrates high incidences of lymph-node metastasis, liver invasion, and peritoneal metastasis, which is similar to the natural course of human gallbladder cancers.
Gemcitabine is a nucleoside analogue that inhibits the synthesis of DNA by interfering with cytidine triphosphate production and by inhibiting the activity of ribonuclease reductase. Gemcitabine is an effective drug approved by the FDA for the treatment of advanced pancreatic cancer. 21 In the present study, the therapeutic success of gemcitabine (estimated by inhibition of tumor growth and prolonged survival) correlated with decreased cell proliferation and increased apoptosis in tumor cells. These results were supported by both PCNA and TUNEL histological staining data. Our results correspond well with those of Okino et al. in which pancreatic tumor cells inoculated subcutaneously in nude mice showed decreased cell proliferation and increased apoptosis after gemcitabine therapy. 22 Our results are compatible with the pharmacological mechanism of gemcitabine incorporating into DNA and causing a pause in DNA synthesis that subsequently induces apoptosis. 23 However, our results of PCNA and Tunnel staining are not distinctive in the chemotherapeutic effect of gemcitabine. Recently, several reports mentioned that the gemcitabine effect may be influenced by the expression of several enzymes involved in the metabolism of gemcitabine. For example, the expression of deoxycytidine kinase (dCK), which is a rate-limiting enzyme in the salvage of deoxyribonucleosides, is correlated to the survival of pancreatic cancer. 24 Cytidine deaminase (CDA) and deoxycytidylate deaminase (DCTD), which are catabolic enzymes of gemcitabine, may be related to the therapeutic response of gemcitabine. 25 Further study will be required to clarify the mechanism of gemcitabine effect for biliary tract cancers by investigating these enzymes.
Studies of the benefit of gemcitabine on the survival of gallbladder cancer patients have yet to be completed. For pancreatic cancers, gemcitabine has demonstrated a survival advantage not only after resection, but also relative to treatment with 5-FU. 21, 26, 27 The data presented here show a significant increase in survival duration resulting from gemcita- bine treatment of gallbladder-cancer-model mice.
Further studies involving human clinical trials will be necessary to confirm the survival benefit of gemcitabine for gallbladder cancer patients.
In conclusion, our findings indicate that gemcitabineÕs mechanism for the inhibition of gallbladder tumor progression and prolonging the survival of orthotopically-inoculated mice may be the inhibition of cell proliferation and the induction of apoptosis. The results of this study, which were derived from a new mouse model of gallbladder cancer, support further clinical testing of gemcitabine for advanced gallbladder cancer in humans. 
